Table 6.
Categories | Sensitivity | Specificity | Early Phase Detection | Late Phase Detection | Expense | Sample Collection and Processing | Reagents and Materials | Facilities Required | Comments | |
---|---|---|---|---|---|---|---|---|---|---|
Cell Culture and Microscopy | Cell Culture and Microscopy | +++ | +++ | ++ | + | +++ | Critical | Expensive | BSL-3 facilities | Not suitable for diagnostic purpose |
Radiology-based detection | Radiology-based Detection | ± | ± | − | + | + | N/A | Large and expensive equipment | Trained personnel | Might be ambiguous with respect to other respiratory diseases |
NAAT-Based Technologies | Real-Time RT-PCR | +++ | +++ | +++ | ± | ++ | Crucial and tedious | Expensive equipment as well as reagents | Trained personnel and BSL-2 facilities | Sensitivity starts to fall after about 8 days of exposure but gold standard method |
Isothermal Amplification Technologies | +++ | +++ | ++ | ± | + | Depends on the method applied | Large scale production can reduce the cost | Trained personnel and BSL-2 facility | Further study required to make it a suitable for POCT | |
CRISPR-Based Diagnostics | +++ | +++ | ++ | ± | + | Depends on the method applied | Large scale use might reduce cost | POCT | Can detect mismatches within DNA with high accuracy | |
Microfluidic Biochip or Lab-On-A-Chip Technology | +++ | +++ | ++ | ± | +++ | Sample processing required | Small amount of sample and reagents required, but production cost is high | POCT | Performed on a single chip with high accuracy | |
Next Generation Sequencing | +++ | ++++ | N/A | N/A | +++ | Tedious | Expensive reagents and equipment required | Trained personnel | Genomic identification and suitable for genomic epidemiological studies | |
Immunoassay | ELISA/CLIA | ++ | +++ | ++ | ± | ++ | Multiple samples can be tested at the same time | Expensive reagent and equipment required for CLIA | Trained professional and BSL-2 facility | Effective for large scale screening in short time |
LFIA | + | +++ | + | − | + | Minimum | Minimum reagent | POCT | Risk of false negative results | |
Neutralization assay | +++ | +++ | ++ | ± | +++ | Sample processing required | Expensive reagent and equipment required | Trained professional and BSL-2 facility | Time consuming | |
Technology Under Development | Aptamer | ++ | ++ | Not enough Data | Not enough Data | ± | Sample processing required | Large scale use will reduce cost | Can be a POCT | Diagnostic performance needs to be evaluated |
Molecular imprinting technology (MIT) | + | + | Not enough data | Not enough data | Not enough data | Sample processing required | Expensive reagent | Can be a POCT | Diagnostic performance is to be evaluated | |
Microarray | ++ | ++ | Not enough Data | Not enough Data | − | Sample processing required | Expensive reagent and equipment required | Qualified personnel and advanced facility | Time Consuming | |
Biosensor | ++ | ++ | Not enough Data | Not enough Data | + | Sample processing required | Expensive reagent | Can be a POCT | Diagnostic performance is to be evaluated |
Notes: “+” Positive/Good; “++” Better; “+++” High; “N/A” Not Applicable; “ ±” Variable; “−” Negative.